Andrew D. Krystal
University of California, San Francisco
313 Papers
1.2K Citations
Andrew D. Krystal is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Insomnia. The author has an hindex of 64, co-authored 271 publications. Previous affiliations of Andrew D. Krystal include Langley Porter Psychiatric Hospital and Clinics & University of California, Berkeley.
Chat about Author
Papers
Examining Experiences of Poor Sleep During Pregnancy: A Qualitative Study to Inform the Development of a Prenatal Sleep Intervention
Jennifer N. Felder,Riya Mirchandaney,J. Harrison,Rachel Manber,Judith Cuneo,Andrew D. Krystal,Elissa S. Epel,Frederick Hecht +7 more
TL;DR: Addressing prenatal sleep problems is an unmet need given the challenges and discomfort women face during pregnancy, and the importance of adequate sleep for promoting mental and physical health during pregnancy.
New Developments in Insomnia Medications of Relevance to Mental Health Disorders.
TL;DR: In this article, a new paradigm for insomnia therapy in which specific drugs are selected to target the specific type of sleep difficulty for each patient includes administering specific treatments for patients with insomnia comorbid with particular psychiatric disorders.
Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial
TL;DR: Six weeks of treatment with esmirtazapine was associated with consistent improvements in objective and patient-reported parameters of sleep onset, maintenance, and duration, and it was generally well tolerated.
Associations of a regulatory polymorphism of monoamine oxidase-a gene promoter (maoa-uvntr) with symptoms of depression and sleep quality
Beverly H. Brummett,Andrew D. Krystal,Ilene C. Siegler,Cynthia M. Kuhn,Richard S. Surwit,Stephan Züchner,Allison E. Ashley-Koch,John C. Barefoot,Redford B. Williams +8 more
TL;DR: Individuals with less active MAOA-uVNTR alleles may be at increased risk for depressive symptoms and poor sleep.
Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study
Philip G. Janicak,Ziad Nahas,Sarah H. Lisanby,H. Brent Solvason,Shirlene Sampson,William M. McDonald,Lauren B. Marangell,Peter B. Rosenquist,W. Vaughn McCall,James Kimball,John P. O'Reardon,Colleen Loo,Mustafa H. Husain,Andrew D. Krystal,William S. Gilmer,Sheila M. Dowd,Mark A. Demitrack,Alan F. Schatzberg +17 more
TL;DR: Initial data suggest that the therapeutic effects of TMS are durable and that TMS may be successfully used as an intermittent rescue strategy to preclude impending relapse.